Literature DB >> 16874487

The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.

Malcolm S Mitchell1, Teri A Lund, Andrew K Sewell, Francesco M Marincola, Elyse Paul, Kim Schroder, Darcy B Wilson, June Kan-Mitchell.   

Abstract

The mucin MUC1 molecule is overexpressed on a variety of adenocarcinomas and is thus, a potential target for immunotherapy. Of the MUC1 peptides that bind to HLA-A*0201(A2), M1.2 (LLLLTVLTV) from the signal sequence appears to be the most immunogenic in humans. Here we have shown that large numbers (10(9)) of tetramer-binding M1.2-specific cytotoxic T lymphocytes (CTL) can be generated ex vivo from circulating precursors, derived from healthy adults. However, there was significant interpersonal variation in the level of co-stimulatory signal required. Tetramer-binding cells also required maturation in culture to become proficient killers of the HLA-A2(+) MUC1(+) MCF7 cell line, known to express a low number of endogenously processed M1.2. The functional avidity of M1.2-specific CTL, however, was low as compared to CTL specific for an HIV-1 epitope. Despite the low avidity, M1.2-specific CTL were polyfunctional, secreting multiple cytokines upon degranulation with antigen recognition. To identify potential agonist peptides that may be superior immunogens, an M1.2-specific CTL culture was used to scan a large nonameric combinatorial peptide library. Of 54 predicted peptides, 4 were "consensus" agonists because they were recognized by CTL from two other donors. Two agonists, p29 (LLPWTVLTV) and p15 (VLLWTVLTV), were equally stimulatory when loaded onto C1R target cells transfected with wild-type HLA-A2. Both agonists induced IL-2, TNF-alpha, IFN-gamma, and degranulation with M1.2-specific CTL. In contrast, production of these cytokines, which are tightly regulated by specific activation through the T cell receptor, was restricted when the CTL were stimulated with peptides loaded onto C1R cells that were transfected with an HLA-A2 molecule bearing a mutation that abrogates binding to the CD8 co-receptor. Thus, activation by both M1.2 and its agonists was dependent upon CD8, showing that compensation by the co-receptor was necessary for the human T cell response to M1.2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16874487     DOI: 10.1007/s00262-006-0191-1

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

1.  Generation of robust CD8+ T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes.

Authors:  Keri L Schaubert; David A Price; Janelle R Salkowitz; Andrew K Sewell; John Sidney; Tedi E Asher; Sylvie E Blondelle; Sharon Adams; Francesco M Marincola; Aviva Joseph; Alessandro Sette; Daniel C Douek; Velpandi Ayyavoo; Walter Storkus; Ming-Ying Leung; Hwee L Ng; Otto O Yang; Harris Goldstein; Darcy B Wilson; June Kan-Mitchell
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

2.  Induction of antigen-specific CTL and antibody responses in mice by a novel recombinant tandem repeat DNA vaccine targeting at mucin 1 of pancreatic cancer.

Authors:  Wen-Chuan Wu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang; Xin-Yu Qin
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-13       Impact factor: 4.553

3.  The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.

Authors:  Jerome Kerzerho; Aurélie Schneider; Emmanuel Favry; Florence Anne Castelli; Bernard Maillère
Journal:  J Biol Chem       Date:  2013-04-03       Impact factor: 5.157

Review 4.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

5.  An Altered gp100 Peptide Ligand with Decreased Binding by TCR and CD8α Dissects T Cell Cytotoxicity from Production of Cytokines and Activation of NFAT.

Authors:  Niels Schaft; Miriam Coccoris; Joost Drexhage; Christiaan Knoop; I Jolanda M de Vries; Gosse J Adema; Reno Debets
Journal:  Front Immunol       Date:  2013-09-04       Impact factor: 7.561

6.  Position-Scanning Peptide Libraries as Particle Immunogens for Improving CD8+ T-Cell Responses.

Authors:  Xuedan He; Shiqi Zhou; Breandan Quinn; Wei-Chiao Huang; Dushyant Jahagirdar; Michael Vega; Joaquin Ortega; Mark D Long; Fumito Ito; Scott I Abrams; Jonathan F Lovell
Journal:  Adv Sci (Weinh)       Date:  2021-10-30       Impact factor: 17.521

7.  The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II-III and metastatic breast cancers.

Authors:  Karen S Anderson; Timothy K Erick; Meixuan Chen; Heather Daley; Margaret Campbell; Yolonda Colson; Martin Mihm; Labib R Zakka; Marika Hopper; William Barry; Eric P Winer; Glenn Dranoff; Beth Overmoyer
Journal:  Breast Cancer Res Treat       Date:  2022-04-28       Impact factor: 4.624

8.  Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope.

Authors:  Keri L Schaubert; David A Price; Nicole Frahm; Jinzhu Li; Hwee L Ng; Aviva Joseph; Elyse Paul; Biswanath Majumder; Velpandi Ayyavoo; Emma Gostick; Sharon Adams; Francesco M Marincola; Andrew K Sewell; Marcus Altfeld; Jason M Brenchley; Daniel C Douek; Otto O Yang; Christian Brander; Harris Goldstein; June Kan-Mitchell
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.